Chuan QIN
Contact:qinchuan@cpl.ac.cn
Academic Experience
2022 - present Member, Academic Advisory Committee, Chinese Academy of Medical Sciences
2021 - present Secretary-General, Consortium of Life Sciences Association, China Association for Science and Technology
2020 - present Director, China National Human Disease Animal Model Resource Center
2018 - present Chairman, International Association for Comparative Medicine
2018 - present Chief editor and Reviewer, Animal Models and Experimental Medicine
2017 - present President, Chinese Association for Laboratory Animal Sciences
2015 - present Scientific Members, International Council for Laboratory Animal Science
2014 - present Chief editor and Reviewer, Acta Laboratorium Animalis Scientia Sinica
2008 - present Chief editor and Reviewer, Chinese Journal of Comparative Medicine
2008 - present Vice President, Asian Federation of Laboratory Animal Science Associations
2003 - present Professor, Institute of Laboratory Animal Sciences, PUMC.
2003 - 2022 Director, Institute of Laboratory Animal Sciences, CAMS.
1994 - 2003 Associate professor, Institute of Laboratory Animal Sciences, PUMC
1993 - 1994 Visiting scholar, Department of laboratory animal pathology, University of Tokyo, Japan
Overview of Academic Research
I. Establishment and application of animal models of infectious diseases (e.g. COVID-19, influenza)
II. Comparative medical study in neurodegenerative diseases
Major Honor and Awards
2019 Second place of State Science and Technology Awards, P.R.China
2019 Kirin science and Technology Award - capital excellent science and Technology Innovation Award, Beijing
2018 Science and technology award of Chinese medical association
2018 Science and technology award of Beijing
2017 The National Award for Excellence in Innovation, P.R.China
2016 Science and Technology Progress Award of Ministry of Education of China
Representative Research Achievements
1.Wang K#, Jia Z#, Bao L#, Wang L#, Cao L#, Chi H#, Hu Y#, Li Q#, Zhou Y#, Jiang Y, Zhu Q, Deng Y, Liu P, Wang N, Wang L, Liu M, Li Y, Zhu B, Fan K, Fu W, Yang P, Pei X, Cui Z, Qin L, Ge P, Wu J, Liu S, Chen Y, Huang W, Wang Q*, Qin CF*, Wang Y*, Qin C*, Wang X*. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature. 2022;603(7903):919-925.
2. Guo Q#, Zhao Y#, Li J#, Liu J#, Yang X#, Guo X, Kuang M, Xia H, Zhang Z, Cao L, Luo Y, Bao L, Wang X, Wei X, Deng W, Wang N, Chen L, Chen J, Zhu H, Gao R, Qin C*, Wang X*, You F*. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host Microbe. 2021;29(2):222-235.e4.
3. Du S#, Cao Y#, Zhu Q#, Yu P#, Qi F#, Wang G, Du X, Bao L, Deng W, Zhu H, Liu J, Nie J, Zheng Y, Liang H, Liu R, Gong S, Xu H, Yisimayi A, Lv Q, Wang B, He R, Han Y, Zhao W, Bai Y, Qu Y, Gao X, Ji C, Wang Q, Gao N, Huang W, Wang Y, Xie XS*, Su XD*, Xiao J*, Qin C*. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell. 2020;183(4):1013-1023.e13.
4. Wang H#, Zhang Y#, Huang B#, Deng W#, Quan Y#, Wang W#, Xu W#, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C*, Lou Z*, Xu M*, Qin C*, Wu G*, Gao GF*, Tan W*, Yang X*. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020;182(3):713-721.e9.
5. Deng W#, Bao L#, Liu J#, Xiao C#, Liu J#, Xue J#, Lv Q#, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu X, Wei Q, Qin C*. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science. 2020;369(6505):818-823.
6. Dai L#*, Zheng T#, Xu K#, Han Y#, Xu L#, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M, Li Y, Cheng H, Yuan Y, Zhang W, Ke C, Wong G, Qi J, Qin C*, Yan J*, Gao GF*. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722-733.e11.
7. Cao Y#, Su B#, Guo X#, Sun W#, Deng Y#, Bao L#, Zhu Q#, Zhang X, Zheng Y, Geng C, Chai X, He R, Li X, Lv Q, Zhu H, Deng W, Xu Y, Wang Y, Qiao L, Tan Y, Song L, Wang G, Du X, Gao N, Liu J, Xiao J, Su XD, Du Z, Feng Y, Qin C*, Qin C*, Jin R*, Xie XS*. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020;182(1):73-84.e16.
8. Gao Q#, Bao L#, Mao H#, Wang L#, Xu K#, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J*, Li C*, Wang X*, Yin W*, Zhang Y*, Qin C*. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
9. Bao L#, Deng W#, Huang B#, Gao H#, Liu J#, Ren L, Wei Q, Yu P, Xu Y, Qi F, Qu Y, Li F, Lv Q, Wang W, Xue J, Gong S, Liu M, Wang G, Wang S, Song Z, Zhao L, Liu P, Zhao L, Ye F, Wang H, Zhou W, Zhu N, Zhen W, Yu H, Zhang X, Guo L, Chen L, Wang C, Wang Y, Wang X, Xiao Y, Sun Q, Liu H, Zhu F, Ma C, Yan L, Yang M, Han J, Xu W, Tan W, Peng X, Jin Q, Wu G*, Qin C*. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583(7818):830-833.
10. Yang W#, Liu Y, Tu Z, Xiao C, Yan S, Ma X, Guo X, Chen X, Yin P, Yang Z, Yang S, Jiang T, Li S*, Qin C*, Li XJ*. CRISPR/Cas9-mediated PINK1 deletion leads to neurodegeneration in rhesus monkeys. Cell Res. 2019;29(4):334-336.